| 000 | 01266cam a2200301 4500500 | ||
|---|---|---|---|
| 005 | 20250121162514.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aLiguori, Claudio _eauthor |
| 700 | 1 | 0 |
_a Manfredi, Natalia _eauthor |
| 700 | 1 | 0 |
_a Renna, Rosaria _eauthor |
| 700 | 1 | 0 |
_a Izzi, Francesca _eauthor |
| 700 | 1 | 0 |
_a Pagliuca, Mauro _eauthor |
| 700 | 1 | 0 |
_a Pagliuca, Francesco _eauthor |
| 700 | 1 | 0 |
_a Biagio Mercuri, Nicola _eauthor |
| 700 | 1 | 0 |
_a Fabio, Placidi _eauthor |
| 245 | 0 | 0 | _aComparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study |
| 260 | _c2020. | ||
| 500 | _a18 | ||
| 520 | _aAimPerampanel (PER) and brivaracetam (BRV) are third-generation antiseizure medications. The aim of the present retrospective, double-centre study was to compare the effectiveness and tolerability between PER and BRV in adult patients with epilepsy. | ||
| 690 | _atolerability | ||
| 690 | _aperampanel | ||
| 690 | _afirst add-on | ||
| 690 | _abrivaracetam | ||
| 690 | _aeffectiveness | ||
| 786 | 0 | _nEpileptic Disorders | Vol 22 | 3 | 2020-03-01 | p. 309-316 | 1294-9361 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-epileptic-disorders-2020-3-page-309?lang=en&redirect-ssocas=7080 |
| 999 |
_c611353 _d611353 |
||